Objective: This study examined whether subcortical volumes of the basal ganglia and thalarnus in schizophrenic patients are related to neuroleptic exposure and symptom se verity. Method: Basal ganglia substructures and thalamic volumes were measured with magnetic resonance imaging in 96 patients with schizophrenia 50 men and 46 women and 128 healthy comparison subjects 60 men and 68 women. Twenty-one of the patients were neuroleptic-naive; of the 75 previously treated patients, 48 had received typical neuroleptics only, and 27 had received typical and atypical neuroleptics. The relation of vol ume measures to treatment status, exposure to neuroleptics, and symptoms was exam ined. Results: The neuroleptic-naive patients did not differ from the healthy comparison subjects in subcortical volumes except for lower thalamic volume. In the neuroleptic-naive group, volumes did not correlate with severity of negative symptoms, but higher volumes in both the thalamus and the putamen were associated with more severe positive symptoms. The previously treated group showed higher volumes in the putamen and globus pallidus than the healthy comparison subjects and the neuroleptic-naive patients. In the treated group, a higher dose of a typical neuroleptic was associated with higher caudate, putamen, and thalamus volumes, whereas a higher dose of an atypical neuroleptic was associated only with higher thalamic volume. Higher subcortical volumes were mildly associated with greater severity of both negative and positive symptoms. Conclusions: Increased subcor tical volumes in treated schizophrenic patients seem to be medication-induced hypertro phy. This hypertrophy could reflect structural adaptation to receptor blockade and may moderate the effects of neuroleptic treatment. Am J Psychiatry 1998; 155:1711-1717 INeuropathological and neuroimaging studies have examined cortical and subcortical aberrations in schizophrenia 1-6. The role of the basal ganglia thalamocortical loop in modulating multiple func tional domains has been substantiated in research on animals and humans 7-10. Interest in the potential role of basal ganglia pathology in schizophrenia has been spurred by the recognition that the basal gan glia regulate not only motor behavior but also aspects of cognitive and limbic behavior 11-13. Extensive connections of thalamic nuclei with cortical and sub-
INeuropathological and neuroimaging studies have examined cortical and subcortical aberrations in schizophrenia 1-6. The role of the basal ganglia thalamocortical loop in modulating multiple func tional domains has been substantiated in research on animals and humans 7-10. Interest in the potential role of basal ganglia pathology in schizophrenia has been spurred by the recognition that the basal gan glia regulate not only motor behavior but also aspects of cognitive and limbic behavior [11] [12] [13] . Extensive connections of thalamic nuclei with cortical and sub-cortical regions buttress their role in gating the cere bral cortex 14, hut few neuroanatomic studies in schizophrenia have examined the thalamus 1-4. Magnetic resonance imaging MRI complements neuropathological investigations of brain structure. While most MRI studies of cortical structures have re ported decreased volume in schizophrenic patients, some studies of the basal ganglia noted increased vol ume in the putamen, globus pallidus 6, 15, 16, and caudate 17. These studies included chronic patients treated with neuroleptics, which may be associated with striatal activation, neuronal hypertrophy, and synaptic adaptation 18, 19. 1-lowever, the association of early onset and lenticular hypertrophy has also been interpreted as supporting a neurodevelopmental model of schizophrenia 15, which attributes enlarged subcortical structures to decreased pruning 20. A longi tudinal study of 29 first-episode patients and 10 com parison subjects, followed for 18 months, reported an increase in caudate volume in the patients relative to SU8CORTICAL MAI VOLUMES the comparison subjects 21. This was associated with younger age and higher exposure to neuroleptics be fore the study. In a study that used an image averaging technique 4, thalamic abnormalities were reported in 39 male patients-most of whom were treated with neuroleptics for several years-compared with 47 healthy men; consistent with other findings 22, 23, the thalamus was smaller in the patients. An assess ment of first-episode neuroleptic-naive patients would help clarify treatment effects.
To permit a comprehensive assessment of intercon nected subcortical structures implicated in the patho physiology of schizophrenia, we evaluated both basal ganglia regions and the thalamus, We compared a group of neuroleptic-naive patients with patients treated with typical and atypical neuroleptics, enabling an initial investigation of relations between volume, symptoms, and type of medication.
METHOD
The study participants were 96 patients 54 inpatients and 42 out patients and 128 healthy comparison subjects from the schizophre nia Mental Health Clinical Research Center at the University of Pennsylvania. The patients had a DSM-lV diagnosis of scluzophre nia 24 established by procedures detailed previously 25. Those with schizophrenifurm disorder at study entry met the criteria for schizophrenia at follow-up. The healthy comparison subjects also underwent standard evaluations 26, 27. There were 21 neurolep tic-naive patients 13 men and eight women and 75 previously treated patients 37 men and 38 women. The groups did not differ in age or parental education, but as expected, the patients had a lower level ot education table 1. The mean ages at unset of illness for the neuroleptic-naivc and previously treated patients were not significantly different, There were five, II, and five left-handers in the neurnleptic-naive, previously treated, and healthy comparison groups, respectively. After complete description of the study, written informed consent`vas obtained from each subject.
Clinical Measures
Rating scales. Evaluations were conducted by trained investiga tors with established procedures intraclass correlation coefficient IICCI >0.85 25. The patients' symptoms were rated on the Scale for the Assessn,ent of Negative Symptoms SANS 28} and the Scale for the Assessment of Positive Symptoms SAPS 291. The groups did not differ on the averaged global ratings of the SANS or the SAPS table I and manifested mild symptoms.
Medkations. A medication record documented for each subject the duration and doses of psychotropics before he or she entered re search center protocols 30, 31. information from records, caregiv ers, and patients was updated at 6-month intervals. Therapeutic in terventions %vere clinically based, starting with typical neuroleptics and introducing atypical neurolepties as indicated. Compliance was assessed by monitoring ingestion, supply, and visits but not blood levels. Total lifetime dose vas quantified in chiorpromazine-equiva lent units in milligrams per kilogram of body weight 32.
Forty-eight patients had been treated with typical neuroleptics only haloperidol, N=28; haloperidol decanoate, N=8; loxapine, N= 6; thioridazine, N=8; molindone, N=3; thiothixene, N=12; fluphen azine, N=4; fluphenazine decanoate, N=4; erifluoperazine, N=9; per phenazine, N7; chlorpromazine, N=8. Ti,e number of patients tak ing various medications exceeds 48 because patients had taken several medications over the course of their illness. The mean dura tion of treatment was 1307.2 days SD=1375.9, range=2-S954, and the mean drug dose was 407.1 chlorproinazine-equivalent units per day SD=25.3, range=65.9-1095.1. Twenty-two patients had been treated with typical and then atypical neuroleptics. The typical neuroleptics were haloperidol N=20, hainperidol decanoate N=1, loxapine N=7, thioridazine N=6, molindone N=3, thiothixene N=5, luphenazine N=7, fluphenazine decanoate N=4, trifluo perazine N=13, perphenazine N=8, and chiorpromazine N=7. The mean duration of treatment with typical neuroleptics was 1259.6 days SD=1371.7, range=1-4238, and the mean dose was 720.4 chlorpromazine-equivalent units per day SD=936.0, range= 58.2-3723.5. The atypical neurolepeics included clozapine N=15 and risperidone N=14. The mean duration of treatment with the atypical neuroleptics was 383.4 days SD=492.8, range=5-1601, and the mean dose was 334.1 chlorprnrnazine-equivalenr units SD= 286.3, range=4.0-919.9. Five patients were treated only with an atypical neurcieptic, risperidone. The mean treatment duration was 70.4 days SD=66.6, range=1-153, and the mean dose was 272.5 chlorpromazine-equivalent units SD=90.6, range=iS0.0-400.0.
MRI Measurements
Acquisition. Scans were acquired on a GE Signa 1.S-T scanner Milwaukee, Wis. with uniform protocol and software. is4lUs spoiled GRASS ptilse sequence, flip angle=35', TR=35 msec, TE=6 msec, field of view=24 cm, number of cxeieations=1 of 1-mm slice thickness were realigned into a standardized transaxial plane along tile anterior cammissure-posterior commissure axis. Three-di,nen sional display and cLitting options derive sagittal and coronal images perpendicular to these transaxial slices withoLie affecting image qual ity for purposes of region drawing.
Volumetric ,neasores. A segmentation algorithm 33, 34 used values of pixels within operator-defined regions of interest, and vol umetric calculations in milliliters for the caudate, putamen, glohus pallidus, and thalamus were performed. The borders of the struc tures were drawn by two investigators RD.M. and V.M. on the ba sis of a neuroanatomy atlas and input from a neuroradiologist ac cording to procedures standardized in our laboratory. The reliability ICC for 10 random cases five patients and five comparison sub jects analyzed independently, without previous exposure to these scatis, was as follows: for the caudate, 0.98; putarnen, 0.99; globus pallidus, 034; thalamus, 0.99. The scans were blinded and mixed, and all analysis was completed by one researcher V.M.. Operators could enlarge scans 16 or inure times to view pixels distinctly around small structures such as the thalamostriate vein, Icept outside the caudate. The delineation between the putamen and the glohus pallidus and the boundaries for the rhalansus were clearer on axial than on coronal images. Boundaries were drawn around the head and body of the catidare nucleus, the putamen, the globus pal lidus, and the thalamus on full gray scale images. After the segnsen tation algorithm was allowed to find the true edge of each nucleus, the lines were drawn at least two pixels from the gray matter edges of the nuclei in the white matter tracts stirrotinding them figure 1, The head of the caudate was defined in the transaxial plane as the mass of gray matter comprising the lateral walls of the lateral ventri cles bounded inferolaterally by the anterior limb of the internal cap sule and superolaterally by the external capsule. Region placement began inferiorly when the operator could see the most inferior aspect of the third ventricle and when the clsiasmatic cistern`vas no longer visible, tist abovc the amygdala. The boundary for the head of the caudate continued superiorly until the thalamus could no longer be visualized, and the anterior horn of the lateral ventricles became confluent with the posterior horn. The body of the caudate was de fined as the portion above the thalamus after the confluence of the antetior and posterior horns of the lateral ventricles. The nucleus ac cumbens was included as caudate. The lenticular nucleus was de fined as the gray matter bounded by the internal and external cap sules. The boundary between the putamen and the globus pallidus was determined by two methods. First, when possible, a strip of white matter was identified between the crisscrossing by fingers of gray matter between the two regions; second, the boundary was noted by the difference in color between the two structures, since the putamen always appeared darker with this acquisition protocol. Botindaries for the globtis pallidus began inferiorly at the level of the third ventricle. They extended superiorly until no mt,re gray matter pixels medial to the boundary for the putainen cotild be detected. Region tracing for the putamen extended superiorly until the thala mus disappeated and the body of the caudate became continuous with the tail. The thalamus was defined as the portion of gray matter bounded medially and posteriorly by the walls of the third ventricle, laterally by the internal capsule, and anteriorly by the fornix and gene of the internal capsule. Region placement began inferiorly above the inferior cnlliculi when the posterior commissure was no longer visible and ended when the third ventricle merged with the posterior horns and the caudate body appeared. A switch from the full gray scale display to a segmentation map was used to verify that no more gray matter pixels were present when a specific region was no longer identified on the nonsegmented MRI.
Data Analysis
The volumes of the caudate, pnramen, globus pallidus, and thala mus were the dependent measures in a group neuruleptic-naive pa tients, previously treated patients, healthy comparison subjects-by region multivariate analysis of covariance MANCOVA, with cra nial volunse as a covariate. Use of this covariate is necessitated by the differences in cranial volume between the sexes and between diag nostic groups. Significant interactions between group and region were decomposed by contrasting each patient subgroup with the healthy comparison group by means of univariare ANCOVAs for each region. The associatioti of volume with medication dose and with treatment dtiration was examined by correlating volumes with total lifetime dose in chlorpromazine-equivalenr units and days of treatment. There were seven patients for whom dose was unavail able for some epochs; they`vere excluded from the correlational analysis. Because of the sample size, the gresup of previously treated patients was subdivided for the correlational analysis into 1 the pa tients treated with typical neuroleptics only N=44 and 2 the pa tieisrs treated with typical followed by atypical ncurolcptics N1 9 combined with the patients treated with atypical neuroleptics only lN=.5. Of the seven patients with missing data, four took typical neurolcprics only, and three were from the cnmhined group. We re peated the analysis including the subjects with missing data by using s C=caudale, P=pulamen, GP=globus pallidus, T=thalamus.
Am J Psychiatry 155:12, December 1998 an estimated average daily dose or excluding missing epnchs. The correlations beLwcen dose and volume were similar with all ap proaches, and so we report here the results of the more conservative elinsination of subjects with missing data.
RESU LTS
The volumes of brain compartments and subcortical regions are presented in table 2. Cranial volume was lower in the male patients than in the healthy compar ison men; among the women it was lower relative to the men in both the patients and the healthy compari son subjects.
The MANCOVAs comparing patient subgroups neuroleptic-naive and previously treated patients with healthy comparison subjects on the four subcorti cal regions showed a main effect of group Hotejling Lawley trace T=0.17 F=126, df=16, 424, p=O.0O3, a main effect of region T=0J7; F=12.15, df=3, 218, Pc 0.0001, and a group-by-region interaction T=0.09; F=3.19, df=6, 434, p=O.004. There was a hemisphereby-region interaction T=0.04; F=2.83, dI=3, 218, p= 0.04 and a group-by-hemisphere-by-region interac tion T=0.06; F=2.11, df=6, 434, p=O.OS. The fojlow up MANCOVAs comparing the neuroleptic-naive pa tients with the healthy subjects on the significant inter actions showed only a marginal group-by-region inter action T=0.0S; F=2.S0, df=3, 144, p=O.O6. The group-by-hemisphere-by-region interaction was not significant. On the other hand, the MANCOVA con trasting the previously treated patients with the healthy comparison subjects showed both a group-byregion interaction T=0.07; F=4.52, df=3, 198, p= 0.004 and a group-by-hemisphere-by-region interac tion T=0.06; F=4.00, dI=3, 198, p=0.008. These ef fects are illustrated in figure 2. As can be seen, the neu roleptic-naive group did nor differ from the healthy comparison group except for a trend for lower tha lamic volume F=3.08, df=1, 148, prO.OS. On the other hand, the previously treated group showed higher volumes for the putamen F=4.86, df=l, 202, p=O.O3 and glohus pallidus F=12.58, df=1, 202, p= 0.0005 upper graphs of figure 2. The interaction with hemisphere reflects the increased left hemispheric globus pallidus volume in treated patients lower right most graph.
Correlations With Medication Dose
The correlations of subcortical volumes with total lifetime medication dose in chlorpromazine-equivalent units are shown in The correlations of subcortical volumes with severity of global positive and negative symptoms were gener ally positive: higher volumes were associated with greater severity. For the neuroleptic-naive group, subcortical volumes were not correlated with severity of negative symptoms, but higher volumes of the thala mus and putamen were associated with more severe positive symptoms r=OiO, df=19, p=O.02, and r= 0.53, df=19, p=O.Ol, respectively. This association was evident for hallucinations caudate r=0.44, df=19, p=O.0'I; putamen r=0.S8, df=19, pc0.01; thalamus r= 0.45, df=19, p=O.04 and bizarre behavior putamen r=0.51, df=19, p=O.Ol. For previously treated pa tients, higher subcortical volumes were associated with greater severity of both negative and positive symp toms. These correlations were small but significant for negative symptoms with volumes of the caudate r= 0.29, df=73, p=O.Ol and putamen r=0.20, df=73, p= 0.05 and for positive symptoms with the putamen r= 0.23, df=73, p=O.02 and globus pallidus r=0.22, df= 73, p=O.OS. Examination of subcategories of symp toms did not point to more specific links. These corre lations were not attenuated by removing medication dose, duration of treatment, current age, age at onset, or duration of illness in partial correlations.
DISCUSSION
This study may help address the origins of subcorti cal hypertrophy reported in patients with schizophre nia by comparing patients never exposed to neurolep tics with treated patients. Differences between groups and correlations between subcortical volumes and dose of medication indicate that exposure to neurolep tics is associated with hypertrophy. The only region that differed between healthy comparison subjects and neuroleptic-naive patients was the thalamus, which was smaller in the patients. While this effect was only marginal in the present study according to a two-tailed test, it does replicate earlier findings of reduced tha lamic volume in schizophrenia 4, 22, 23. Thus, there is some convergence of evidence from neuropathologi cal and neuroimaging studies that suggests thalamic abnormalities in schizophrenia 1-4. This could pro vide neurobiological substrates for a range of behav ioral deficits related to gating that are associated with thalamic and thalamocortical circuitry 35, 36. Across subcortical regions, with the exception of the caudate, it appears that patients treated with neurolep tics show hypertrophy relative to their neuroleptic-na ive counterparts and to healthy comparison subjects. The suggestion that increased subcortical volume is re lated to exposure to neuroleptics is further strength ened by the positive correlations between medication dose and volumes. Note that for patients treated with typical neuroleptics only, correlations were evident also in the caudate. Little is known from neuroimaging research about the effects of neuroleprics on brain vol ume. There are preliminary data suggesting that antipsychotics may he related to volume changes in both subcorrical regions 21, 37, 38 and cortical regions 31. DeLisi eta!. 38 observed larger caudate and len ticular nuclei volumes in chronic patients than in firstepisode patients. In a longitudinal study, Chakos et al.
21 reported a 5.7% increase in caudate nuclei in firstepisode patients taking typical neuroleptics. Reversal of caudate volume increase was seen in patients who were switched to clozapine in comparison with those who continued to take typical neuroleptics 37. In a longitudinal design, we found that in first-episode pa tients, a greater rate of reduction in frontal and tempo ral lobe volumes was associated with improvement of delusions and thought disorder and a higher dose of typical neuroleptics 31. It is noteworthy that in the present study, the dose of atypical neuroleprics is asso ciated with bilaterally higher volumes only in the thaI amus. This perhaps is related to differences in mode of action.
Morphometric MRI studies that examined cortical regions of interest have generally reported an associa tion between decreased parenchymal volume and greater symptom severity 39, 40. We found small but consistently positive correlations between subcortical volumes and severity of both positive and negative symptoms. This further supports the possibility that the hypertrophy associated with neuroleptic exposure reflects adaptive up-regulation of the occupancy of dopamine receptors 18, 19, 21, with concomitant persistence of symptoms. Indeed, as we see in the neu roleptic-naive group, before intervention with neuro leptics, higher subcortical volumes are quite specifi cally related to more severe positive symptoms, such as hallucinations and bizarre behavior. In patients treated with neuroleptics, this association, while attenuated, is generalized to both positive and negative symptoms. Thus, larger subcortical volumes portend more severe symptoms regardless of whether these volumes reflect endogenous processes or the effects of treatment.
Our results also suggest that the increase in volume is more pronounced in the left globus pallidus, and the correlations are consistently higher for left hemispheric subcorrical regions. Lateralized abnormalities have been implicated in schizophrenia in some structural and functional neuroimaging studies as well as in post mortem studies 1, 31, 41. This supports hypotheses of lateralized brain dysfunction in schizophrenia 42.
While we have observed substantial effects of neuro leptic exposure and dose, we should caution against interpreting all of the differences between the neuro leptic-naive and treated groups as demonstrating med ication effects. Although we attempted to control for variables that could conceivably influence volume measures, the attribution of volume differences to medication must await longitudinal study. Such studies could also address more powerfully the relation be tween volume changes and response to treatment 21, 31. However, our results can rule out an explanation of subcortical hypertrophy as reflecting purely a lack of neuronal pruning as part of a neurodevelopmental aberration 15, 20. Medication type and dose also need scrutiny 37. Similarly, further parceling of brain regions will permit assessment of the reciprocity be tween cortical and subcortical anomalies.
Neuroanatomic studies have implicated multiple brain regions and their connecting circuitry; this may underlie the pervasive deficits evident in schizophrenia. While there are some inconsistencies in MRI structural studies of subcortical regions, most report either in creased volume of basal ganglia structures in schizo phrenic subjects or no difference from the structures of healthy people. There are few studies of the thalamus, and they suggest decreased volume in schizophrenic subjects. The critical role of neuroleptic intervention by modulating neurotransmitters needs to be ad dressed in neuroanatomic studies that use large study groups with controlled intervention. This study was limited by the lack of prospective therapeutic inter vention with specific medications. However, the re sults encourage further integration of anatomic and clinical data with neurocognitive and functional neuroimaging. The course of treatment response in first-episode and chronic schizophrenia. glomerull with recovery of histological changes: almost all were normocellular with open capillary lumina, with only occasional glomeruh having mild tuft collapse and mild periglomerular fibrosis. The lntersltltum showed only mild tubular dilatation figure, B. Electron microscopy showed near normal podocytes and dIsappearance of pseudocrescents; endotlielial cytoplasmic inclusions were absent. 14 weeks after stopping dialysIs his serum urea was 8 mmol/L and creatinlne 132 ismol/L, urlnaty protein 0-6 gIL, serum albumIn 39 gIL, total cholesterol 59 nmoliL, and 04 count 0-12>< 10'IL, Serum HIV-RNA by branched chain DNA assay was less than 500 copies/mL.
A report by UNAIDS Indicates that approximately 7000 young people contract l-{IV-1 Infection every day worldwide; 5-10% will develop nephropathy and end-stage renal disease, with a prevalence of HIV-1-associated end-stage renal disease as high as 38% in some inner city hospitais in the USA! Our patient had typical clinical features of HIV-1 nephropathy wIth heavy proteinuria and absent peripheral oedema, rapid progression to dialysIs-dependent renal failure without hypertension, normal-sized kidneys on ultrasound examination, and pathological features of collapsing giomerulopathy with cystic dilation of the tubules and endothellal cells containing tubuioreticular cytoplasmic inclusions.' This case supports the hypothesis that viral proteins and/or the host of cytoklnes released during active viral replication can have cytopathic effects on the kidneys;'' however, it Is also possibie that nephropathy may occur as a result of direct infection of the glomerular and tubular epithelial cells by HIV-1 in susceptIble patients since HIV-1 has been shown to be in the kidneys of seropositive individuals both with and without nepropathy.
Antiretroviral treatment can improve glomerular and tubular histopathological changes of 1-IIV-1-associated nephropathy in dialysis-dependent patients. Other reports have indicated some transient improvement in renal function and proteinurla in patients with nephropathy after treatment with steroids. anglotensin-converting enzyme blockers,4 or zidovudine,' though most of these patients ultimately required long-term dialysis. Whether early initIation of anti-retroviral therapy, before substantial fibrosis occur, results In optimum benefit is unknown. The response of our patient to triple antiretroviral therapy suggests that studies may be warranted to determine whether such therapy may obviate the need for long-term dialysis in some patients. Brain atrophy was assessed on a visual scale, on which 0-1 meant no changes or dubious atrophy and 2-3 meant moderate or severe atrophic changes. After 5 years of illness, we found significant progression of frontal atrophy In 21 schizophrenic patients, compared with nine consecutively included healthy volunteers. We saw progressive frontal atrophy in ten non-schizophrenic patients, but to a lesser degree. During follow-up, schizophrenic patients recieved a median of 172 040 mg range 19 540-928 450 neuroleptic medication chiorpromazine equivalents. Seven nonschizophrenic patients received a median of 20780 mg range 678-141596. The only atypical neuroleptic used was clozapine. administered to three patients, always in high doses and in combination with traditional neuroleptics.
Patients were thought to have a chronic, non-remittent course of illness if all psychiatric records described a state of permanent psychosis, and If they were psychotic at the time of the reinvestigation, Some patients were described as remitted, but if in long interviews they showed firm delusive systems that seemed to be integrated but not necessarily overt parts of their lives, and If they were Judged to he permanently deluded, despite their records, they were classified as non-remittent. This classification was made without knowledge of the results of the CT scans. Nine schizophrenic patients eight men and one woman had been continuously psychotic during follow-up. At reinvestigation. non-remittent patients had significantly higher ratings for psychopathology SANS and SAPS2 than remittent patients.
Because of the small sample, we did exact tests in a logistic regression analysis with LogXact, adjusted for sex, course of illness, remIssIon/non-remission, diagnosis, and neuroieptic mad. Course of illness and diagnosis had no significant impact on the development of frontal atrophy. Sex was significant pO.O3fi If course of illness was not included into the model, but sex became non-significant p.O. 138 If course of Illness was included. Neuroleptic load was significant whether sex was included or not p.0.013 and 0.0003, respectively. The estimated risk of atrophy increases by 6496 for each additional lOg neuroleptic drug. Non-remittent patients received a higher neuroleptic dose than remittent patients, but the model was corrected for this Interaction.
Association has been shown between frontal atrophy or aplasla and non-respondence to antipsychotic drugs,' and neuroleptic side-effects as tardive dyskinesla and akathisia have been associated with wider suici.' These studies do not include neuroleptic load as a possible explanatory factor for the anormalities found. Traditional neuroleptics have been shown to affect brain structure because they enhance the volume of basal ganglia,5 but the potential Impact of neuroieptlcs. on frontal cortex, for example, is not known.
Factors causing progression of brain atrophy have not yet been Identified. Our study showed an unexpected effect of
